•
Sep 30, 2024

AptarGroup Q3 2024 Earnings Report

AptarGroup reported strong Q3 2024 results with growth in proprietary drug delivery systems and increased demand for closure technologies.

Key Takeaways

AptarGroup's Q3 2024 results showed a 2% increase in both reported and core sales, driven by the Pharma and Closures segments. Net income increased by 19% to $100 million, and adjusted EPS rose by 6% to $1.49.

Reported and core sales increased by 2%.

Reported EPS increased 17% to $1.48, and adjusted EPS increased 6% to $1.49.

Reported net income increased 19% to $100 million.

Pharma segment delivered reported sales growth of 8% and core sales growth of 7%.

Total Revenue
$909M
Previous year: $893M
+1.8%
EPS
$1.49
Previous year: $1.39
+7.2%
Total Core Sales Growth
2%
Previous year: 2%
+0.0%
Beauty + Home Core Sales Growth
-6%
Previous year: 2%
-400.0%
Pharma Core Sales Growth
7%
Previous year: 8%
-12.5%
Gross Profit
$351M
Previous year: $326M
+7.5%
Cash and Equivalents
$328M
Previous year: $152M
+116.3%
Free Cash Flow
$163M
Previous year: $97.2M
+67.4%
Total Assets
$4.63B
Previous year: $4.3B
+7.6%

AptarGroup

AptarGroup

AptarGroup Revenue by Segment

Forward Guidance

Aptar anticipates a solid finish to a strong year, with top-line growth expected in Q4 despite some customer inventory adjustments. Pharma is expected to finish within its core sales long-term target range, and Closures expects a strong finish with healthy margin improvements. Beauty continues to focus on the bottom line in a tough macro environment.

Positive Outlook

  • Top line is expected to grow in the fourth quarter.
  • Pharma business should finish full year 2024 within its core sales long-term target range of 7-11%.
  • Pharma segment will deliver solid, double-digit adjusted EBITDA growth in 2024 due in part to sales of higher value products and royalties.
  • Closures segment has returned to growth and we expect a strong finish to 2024, with healthy adjusted EBITDA margin improvements over the prior year.
  • Full year adjusted EPS would be in the range of $5.34 to $5.42, a double-digit increase over full year 2023.

Challenges Ahead

  • Some customers have indicated seasonal inventory right-sizing in the beauty and cough & cold end markets.
  • Beauty is battling a tough macro environment.
  • Innovation, cost mitigation, improved operational leverage and accelerating efficiencies remain key priorities for our teams.
  • Aptar currently expects earnings per share for the fourth quarter of 2024, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.22 to $1.30.
  • This guidance is based on an effective tax rate range of 20% to 22% with a comparable adjusted prior year effective tax rate of 24%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income